Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic

Thrombosis Research

Volumn 129, Issue 5, 2012, Pages

  Salaj, Peter ^a   Penka, Miroslav ^b   Smejkal, Petr ^b   Geierova, Vera ^a   Ovesná, Petra ^c   Brabec, Petr ^c   Cetkovsky, Petr ^a   Kubes, Radovan ^d   Mesterton, Johan ^e   Lindgren, Peter ^e,f  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^e OptumInsight   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cost effectiveness; Haemophilia; Plasma derived activated prothrombin complex concentrate; Recombinant factor VIIa; Registry

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7A; PLASMA DERIVED ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT ACTIVATED FACTOR VIIA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; CZECH REPUBLIC; HEALTH CARE COST; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; PATIENT CARE; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; CZECH REPUBLIC; DRUG COSTS; FACTOR VIIA; HEMOPHILIA A; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860432036     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.02.005     Document Type: Article

References (19)

1. P. Smejkal, P. Brabec, M. Matyskova, A. Bulikova, M. Slechtova, and J. Kissova FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre Haemophilia 15 2009 743 751
2. C. Knight, A.M. Dano, and T. Kennedy-Martin Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors Adv Ther 26 2009 68 88
3. M.J. Treur, F. McCracken, B. Heeg, A.V. Joshi, M.F. Botteman, and F. De Charro Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression Haemophilia 15 2009 420 436
4. A.V. Joshi, J.M. Stephens, V. Munro, P. Mathew, and M.F. Botteman Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor to moderate bleeds in hemophilia patients with inhibitors Curr Med Res Opin 22 2006 23 31
5. M.C. Ozelo, P.R. Villaça, J.O. De Almeida, T.M. Bueno, P.A. De Miranda, and W.M. Hart A cost evaluation of treatment alternatives for mild to moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil Haemophilia 13 2007 462 469
6. C.W. You, S.Y. Lee, and S.K. Park Cost and effectiveness of treatments for mild to moderate bleeding episodes in haemophilia patients with inhibitors in Korea Haemophilia 15 2009 217 226
7. K.A. Lyseng-Williamson, and G.L. Plosker Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX Pharmacoeconomics 25 2007 1007 1029
8. J.M. Stephens, A.V. Joshi, M. Sumner, and M.F. Botteman Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors Expert Opin Pharmacother 8 2007 1127 1136
9. C. Knight, A.M. Dano, and T. Kennedy-Martin A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors Haemophilia 15 2009 405 419
10. K.G. Putnam, R.L. Bohn, B.M. Ewenstein, W.C. Winkelmayer, and J. Avorn A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors Haemophilia 11 2005 261 269
11. K. Steen Carlsson, J. Astermark, S. Donfield, and E. Berntorp Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor Thromb Haemost 99 2008 1060 1067
12. J.W. Hay, and Z.Y. Zhou Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors Haemophilia 17 2011 e969 e974
13. P. Salaj, P. Brabec, M. Penka, V. Pohlreichova, P. Smejkal, and P. Cetkovsky Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic Haemophilia 15 2009 752 759
14. Státní ústav pro kontrolu léčiv 2009 http://www.sukl.cz/seznam-hrazenych-lp-pzlu-k-1-9-2009 Accessed 25 November 2011
15. Economic information on health care Published by Ústav zdravotnických informací a statistiky ČR, Praha 2, Palackého nám. 4 2007 http://www.uzis.cz Accessed 25 November 2010
16. G. Dunn, M. Mirandola, F. Amaddeo, and M. Tansella Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review Br J Psychiatry 183 2003 398 404
17. J.W. Hardin, and J.M. Hilbe Generalized Linear Models and Extensions 2007 Stata Press College Station, TX
18. K. Kavakli, A. Yesilipek, B. Antmen, S. Aksu, C. Balkan, and D. Yilmaz The value of early treatment in patients with haemophilia and inhibitors Haemophilia 16 2010 487 494
19. J.M. Lusher Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII Blood Coagul Fibrinolysis 11 Suppl. 1 2000 S45 S49